AU2018269935B2 - Compositions and methods for the treatment of complications and disorders relating to von Willebrand factor - Google Patents

Compositions and methods for the treatment of complications and disorders relating to von Willebrand factor Download PDF

Info

Publication number
AU2018269935B2
AU2018269935B2 AU2018269935A AU2018269935A AU2018269935B2 AU 2018269935 B2 AU2018269935 B2 AU 2018269935B2 AU 2018269935 A AU2018269935 A AU 2018269935A AU 2018269935 A AU2018269935 A AU 2018269935A AU 2018269935 B2 AU2018269935 B2 AU 2018269935B2
Authority
AU
Australia
Prior art keywords
vwf
synthetic polynucleotide
synthetic
disorder
aptamer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018269935A
Other languages
English (en)
Other versions
AU2018269935A1 (en
Inventor
James C. Gilbert
Shuhao Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Band Therapeutics LLC
Original Assignee
Band Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Band Therapeutics LLC filed Critical Band Therapeutics LLC
Publication of AU2018269935A1 publication Critical patent/AU2018269935A1/en
Application granted granted Critical
Publication of AU2018269935B2 publication Critical patent/AU2018269935B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/316—Phosphonothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
AU2018269935A 2017-05-19 2018-05-18 Compositions and methods for the treatment of complications and disorders relating to von Willebrand factor Active AU2018269935B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762508530P 2017-05-19 2017-05-19
US62/508,530 2017-05-19
US201862638579P 2018-03-05 2018-03-05
US62/638,579 2018-03-05
PCT/US2018/033376 WO2018213697A1 (en) 2017-05-19 2018-05-18 Compositions and methods for the treatment of complications and disorders relating to von willebrand factor

Publications (2)

Publication Number Publication Date
AU2018269935A1 AU2018269935A1 (en) 2019-11-28
AU2018269935B2 true AU2018269935B2 (en) 2024-05-16

Family

ID=64274836

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018269935A Active AU2018269935B2 (en) 2017-05-19 2018-05-18 Compositions and methods for the treatment of complications and disorders relating to von Willebrand factor

Country Status (11)

Country Link
US (3) US11060094B2 (https=)
EP (1) EP3624801A4 (https=)
JP (2) JP7317805B2 (https=)
KR (1) KR102830459B1 (https=)
CN (2) CN110520128B (https=)
AU (1) AU2018269935B2 (https=)
CA (1) CA3058001A1 (https=)
IL (1) IL269641B2 (https=)
MX (1) MX390865B (https=)
TW (1) TWI806868B (https=)
WO (1) WO2018213697A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021158583A1 (en) * 2020-02-04 2021-08-12 Band Therapeutics, Llc Regulation of von willebrand factor (vwf)
KR20220150303A (ko) * 2020-02-04 2022-11-10 다케다 야쿠힌 고교 가부시키가이샤 재조합 vwf의 투여에 의한 중증 폰 빌레브란트병 환자의 월경과다 치료
US20240002861A1 (en) * 2020-11-24 2024-01-04 Band Therapeutics, Llc Compositions and methods for treatment of bleeding disorders
CN116723863A (zh) * 2020-11-24 2023-09-08 邦德治疗有限公司 用于治疗出血性病症的组合物和方法
US12090243B2 (en) 2021-03-24 2024-09-17 Aleo Bme, Inc. Compositions comprising fluid gels for tissue separation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010091396A2 (en) * 2009-02-09 2010-08-12 Archemix Corp. Aptamers to von willerbrand factor and their use as thrombotic, hematologic and cardiovascular disease therapeutics

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7566701B2 (en) 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
KR20070101227A (ko) * 2004-09-07 2007-10-16 아케믹스 코포레이션 폰 빌레브란트 인자에 대한 앱타머 및 이의 혈전증치료제로서의 용도
US7563601B1 (en) * 2005-06-01 2009-07-21 City Of Hope Artificial riboswitch for controlling pre-mRNA splicing
US20110118187A1 (en) * 2006-10-19 2011-05-19 Duke University Reversible platelet inhibition
US20090203766A1 (en) * 2007-06-01 2009-08-13 Archemix Corp. vWF aptamer formulations and methods for use
WO2015163458A1 (ja) * 2014-04-24 2015-10-29 株式会社リボミック オートタキシンに結合しオートタキシンの生理活性を阻害するアプタマー及びその利用
EP3266871B1 (en) * 2015-03-06 2021-04-28 TAGCyx Biotechnologies Inc. Method for stabilizing dna aptamers
KR102640903B1 (ko) 2015-10-30 2024-02-27 탁시스 바이오 가부시키가이샤 vWF에 결합하는 DNA 앱타머
WO2021158583A1 (en) * 2020-02-04 2021-08-12 Band Therapeutics, Llc Regulation of von willebrand factor (vwf)
US20240002861A1 (en) * 2020-11-24 2024-01-04 Band Therapeutics, Llc Compositions and methods for treatment of bleeding disorders
WO2023039522A1 (en) * 2021-09-10 2023-03-16 Guardian Therapeutics, Llc Fatty acid conjugates of nucleic acids

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010091396A2 (en) * 2009-02-09 2010-08-12 Archemix Corp. Aptamers to von willerbrand factor and their use as thrombotic, hematologic and cardiovascular disease therapeutics

Also Published As

Publication number Publication date
US20210292763A1 (en) 2021-09-23
IL269641B2 (en) 2024-12-01
JP2020522566A (ja) 2020-07-30
US11060094B2 (en) 2021-07-13
MX2019013700A (es) 2020-01-15
IL269641B1 (en) 2024-08-01
EP3624801A4 (en) 2021-02-24
CN110520128A (zh) 2019-11-29
IL269641A (en) 2019-11-28
JP7781815B2 (ja) 2025-12-08
KR20200008122A (ko) 2020-01-23
WO2018213697A1 (en) 2018-11-22
KR102830459B1 (ko) 2025-07-09
TW201900877A (zh) 2019-01-01
JP7317805B2 (ja) 2023-07-31
AU2018269935A1 (en) 2019-11-28
CN117487811A (zh) 2024-02-02
RU2019136508A (ru) 2021-06-22
EP3624801A1 (en) 2020-03-25
MX390865B (es) 2025-03-12
CN110520128B (zh) 2023-11-14
CA3058001A1 (en) 2018-11-22
NZ758741A (en) 2025-09-26
US20200165612A1 (en) 2020-05-28
JP2023093535A (ja) 2023-07-04
RU2019136508A3 (https=) 2022-02-14
TWI806868B (zh) 2023-07-01
US20260092283A1 (en) 2026-04-02

Similar Documents

Publication Publication Date Title
US20260092283A1 (en) Compositions and methods for the treatment of complications and disorders relating to von willebrand factor
PT2596807E (pt) Aptâmeros de ligação ao complemento e agentes anti-c5 úteis no tratamento de distúrbios oculares
US20090203766A1 (en) vWF aptamer formulations and methods for use
IL307655A (en) Factor xi inhibitors, compositions comprising same and uses thereof
US20240417739A1 (en) Compositions and methods for treatment of bleeding disorders
US20090163437A1 (en) Steady-state subcutaneous administration of aptamers
US20230038761A1 (en) Regulation of von willebrand factor (vwf)
AU2013355043A1 (en) Oligonucleotide formulation
RU2806844C2 (ru) Композиции и способы лечения осложнений и нарушений, связанных с фактором фон виллебранда
KR20240139057A (ko) 프리칼리크레인(pkk) 단백질의 발현을 억제하기 위한 조성물 및 방법
JP2022531874A (ja) 細胞におけるｐｒｏｓ１の発現を阻害するための核酸
KR20210116509A (ko) Serpinc1 irna 조성물 및 그의 이용 방법
HK40102681A (zh) 用於治疗血管紧张素原(agt)相关病症的方法和组合物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)